• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Blog
  • News & Events
  • Videos
  • Resources
main-logo-small

Compliance Architects

Consulting Technology Outsourcing

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us
|||

Data Integrity: The Foundation of Medical Product Manufacturing Compliance

The FDA and other global regulators rely on reviews of data during inspections to determine whether a pharmaceutical or medical device manufacturer is operating within regulatory requirements and expectations. The credibility of that data is a crucial parameter in the regulator’s assessment of whether operations are compliant—or not. Data integrity refers to the credibility—meaning reliability, validity, authenticity and trustworthiness—of various data presented for regulator review. Questions about the integrity of data presented in regulator-reviewed documentation always raise red flags about the compliance state of your operation and the levels of control within the medical product manufacturing system.

Since data collection and reporting are foundational for virtually all cGMP and QSR requirements, the notion of data integrity is foundational to all aspects of regulatory compliance. And today, all regulators, FDA and other international bodies, take the concept very seriously. Questions about data integrity are among those most frequently appearing as FDA Form 483 observations and warning letter citations. Out of 15 cGMP-related warning letters issued to drug firms and four QSR-related letters to device companies in 2019 and posted to the FDA website, approximately nine included at least one citation related to data integrity, according to a review by Compliance Architects®.

The issue was highlighted by a Bloomberg article last year, which examined ongoing issues at Mylan manufacturing sites, many involving data integrity.

And this is most definitely not a new trend. In a January 2017 guest column for Pharmaceutical Online, Barbara Unger of Unger Consulting highlighted the emphasis on data integrity in FDA enforcement activity during the 2013-2016 period. Figure 1, below, illustrates this growing emphasis going back years now.

Figure 1: FDA Data Integrity Enforcement Trends

It’s important to note that the words “data integrity” may not appear in such citations. Rather, companies might see such statements as the following:

  • Raw materials, intermediates, and finished API analytical results found to be failing specifications or otherwise suspect (e.g. OOT) are retested until acceptable results are obtained. These failing or otherwise suspect results are not reported.
  • Failure to document production and analytical testing activities at the time they are performed.
  • Failure to prevent unauthorized access or changes to data and to provide adequate controls to prevent omission of data.
  • Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
  • Failure to maintain complete data derived from all testing, and to ensure compliance with established specifications and standards.
  • During our inspection, we observed multiple examples of incomplete, inaccurate, or falsified laboratory records.

And although the wording may vary, all such citations relate to the faith—or lack thereof—that agency investigators have in the information provided by drug and device companies about their manufacturing operations. Characteristics that the FDA considers when determining the credibility of data include attributability, legibility, contemporaneous recording, originality and accuracy, often abbreviated as ALCOA.

Companies can avoid regulatory and other fallout due to poor data integrity practices by comprehensively implementing a seven-program-element approach within their overall quality systems (see box above).

Filling the data integrity gaps

To fully understand the concept of data integrity, medical product manufacturers need a clear picture of what comprises data from the FDA and other regulators perspective. Examples of data include charts that record information, paper and electronic lab notebooks, product release and approval information, batch release documentation, certificates of analysis, raw data, instrument printouts and computer-based data, among others.

Companies can face numerous obstacles to having reliable data and information to present for inspections. Many challenges come down to unintentional errors or negligent conduct due to:

  • Lack of awareness;
  • Lack of defined expectations from management;
  • Lack of procedural or positive controls;
  • Lack of adequate supervision and oversight;
  • Failure to prioritize importance of data integrity;
  • Tolerance for sloppy or unprofessional work;
  • Lack of periodic “checks” on performance;
  • Lack of technology controls;
  • Pressure on personnel to achieve outcomes; and
  • A “whatever it takes” culture.

And in some instances, data integrity gaps may be due to purposeful, deliberate conduct aimed at gaining monetary, professional or personal gain. This can occur when the risk from non-compliance is greater than that from wrongful conduct. If management creates a culture that presents data manipulation as a victimless crime, or directs staff to fudge numbers to meet customer service requirements or for financial gain, employees may fail to ensure the integrity of data presented in FDA-facing records that are reviewed during inspections.

But the FDA and other regulators don’t care whether data integrity gaps are due to deliberate or unintentional acts. As far as FDA is concerned, if it cannot rely on the data, then it cannot be assured that manufacturing operations are compliant. And the ramifications for noncompliance can be serious—both in enforcement and customer perception terms—for pharma and medical device manufacturers.

As with other cGMP and QSR requirements, the FDA expects medical product manufacturers to apply a risk-based approach to data integrity. The overall data integrity compliance risk profile is the sum of all data integrity gaps, which can be grouped into three categories: known and documented gaps, known and undocumented gaps, and unknown, undocumented gaps.

Pharma and medical device manufacturers are responsible for identifying, documenting and addressing all gaps. Thus, the first step toward ensuring data integrity across all quality-related systems and activities is a comprehensive assessment of all potential gaps, so that all areas of concern are identified (known) and documented.

Using the comprehensive seven-program-element approach (listed in the box above), companies can be confident that this structural approach will maximize the prospect of ensuring data integrity throughout all operations. Figure 2, below, illustrates how several of the seven program elements, which Compliance Architects® will explore in greater depth in future articles, can work together to create a comprehensive data integrity program that produces data in which the FDA and other regulators will have faith.

Figure 2: How It Fits Together – A Structural Approach

Filed Under: Achieving Compliance, data integrity, FDA Enforcement Tagged With: FDA Data Integrity

Primary Sidebar

Sign Up To Our Newsletter

You May Also Like

Proud to be a Silver Sponsor of RIC’s Inaugural Annual Meeting! Join us March 22-23, 2023 at Convene in Arlington, VA!

Compliance Architects is proud to be Silver Sponsor of this year's RIC's inaugural annual meeting! The REMS Industry Consortium fosters collaboration and innovation to advance

Join the Team at Compliance Architects as our Content Marketing Manager!

This excellent opportunity will require the successful candidate to lead the technical content marketing and marketing automation activities as well as enable, manage, and drive
life sciences staffing

Talk to us about current talent trends, and what the industry will need in the next 5 to 10 years?

Transcript taken from 2022 PMWS by Executive Platforms The talent crisis as it has been called is certainly not something that has gone away or

Footer

Compliance Architects®

  • Contact Us
  • (888) 734-9778
  • info@compliancearchitects.com

Quick Links

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us

Our Services

  • Inspection Readiness & Enforcement
  • FDA Quality Consulting – Systems and Training
  • Quality Assurance and Engineering
  • Corporate Compliance and Litigation Services
  • FDA Regulatory Consultants – Due Diligence
  • Quality, Compliance, Regulatory & Operations’ Staffing Services

Proprietary Solutions

  • Writing for Compliance®
  • Quality Pulse®
  • CRPN Quality Roadmap®

© 2009-2023 Compliance Architects Holdings LLC – used by permission. All copyrights, trademarks and other intellectual property are the property of Compliance Architects Holdings LLC and are used by permission.

  • Debarment Certification Statement
  • Privacy Policy
  • Terms of Use

Contact Us Today

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT